



Altimune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021

October 6, 2021 at 4:01 PM EDT

GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences:

- **H.C. Wainwright 5th Annual NASH Investor Conference**
Tuesday, October 12, 2021
3:30 pm Eastern Time
- **H.C. Wainwright Hepatitis B Virus (HBV) Virtual Conference**
Wednesday, October 13, 2021
4:30 pm Eastern Time

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Investor & Media Contacts:

Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com



Source: Altimune, Inc